database > company
Lixte Biotech
Biotech Specialty Pharma
248 Route 25A No. 2
East Setauket, NY 11733 USA
phone:631.830.7092
fax:928.982.5050
Symbol LIXT.OB
Exchange OTC
Founded 0
Employees
          www.lixte.com
Research Sector Biotech Specialty Pharma
Summary Description
A cancer therapeutics and diagnostics company dedicated to bringing improved treatments of human cancers to clinical practice.
Management
President and Founder: John S. Kovach, M.D.
Ownership
Financials Mkt Cap :22
* numbers in thousands
 
Keywords
cancer, diagnostics, drug discovery, glioblastoma multiforme, GBM, neuroblastoma, medulloblastoma, pancreatic cancer.


Comment | Printable Version | Modify profile Oct. 17, 2009

Description
LIXT.OB was originally founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to cancer drug discovery research that is primarily focused on the development of compounds for malignancies with few effective treatment options - such as certain types of brain cancer (glioblastoma multiforme or GBM, neuroblastoma, and medulloblastoma) and pancreatic cancer.
Products / Services
One lead compound (LB-1) is the most advanced in the process and Lixte plans to be ready for IND submission in mid-2010. The other lead compound (LB-2.5), which inhibits cancer cells by a different mode of action compared to LB-1, is anticipated to complete its evaluation by the end of 2010.
Technology / Differentiation
One lead compound (LB-1) is the most advanced in the process and Lixte plans to be ready for IND submission in mid-2010. The other lead compound (LB-2.5), which inhibits cancer cells by a different mode of action compared to LB-1, is anticipated to complete its evaluation by the end of 2010.
Strategy
The Company's primary goal is to begin preclinical studies for its two lead compounds, which is a requirement for submitting an IND application to the FDA to begin human clinical trials. Lixte will choose its lead compound based in part upon discussions with the Agency at a pre-IND meeting and the Company will also begin preclinical studies for a second compound if sufficient resources are available. The secondary goal for Lixte is to further characterize the anti-fungal activities for select derivative compounds of the LB-200 series, which will be done in collaboration with academic partners. The Company recently confirmed that its lead compound of the LB-200 series has shown the potential to safely (no evidence of toxicity was observed) cure two common types of fungal skin infections in a guinea pig model through topical application of the compound on a daily basis for two weeks.